PATENT CLAIM ANALYSIS

Application Number: 15744531
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2019-01
Patent Classification: ["514", "021200"]

Abstract:
The present disclosure provides human tear lipocalin muteins that specifically bind to LAG-3, which can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases. The present disclosure further shows the human lipocalin muteins can inhibit the binding of LAG-3 to MHC class II on cells overexpressing MHC class II. The present disclosure also concerns methods of making LAG-3 binding lipocalin muteins described herein as well as compositions comprising such lipocalin muteins. The present disclosure further relates to nucleic acid molecules encoding such lipocalin muteins and to methods for generation of such lipocalin muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these lipocalin muteins as well as compositions comprising one or more of such lipocalin muteins.

Claim (Index 26):
A host cell containing a nucleic acid molecule of  claim 24 .

Metadata:
- Claim Count in Document: 2.0
- Percentile: 86.0
- Lexical Diversity: 2.01316
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15371698', '14402438', '14208629', '14839222', '12865237']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.886176418089125
- 35 USC 102 Novelty (BERT): 0.6297606097224704
- Combined Prediction Score: 0.8605348372524595
- Mean Citation Score: 665.3214340000002
- Max Citation Score: 679.7365
- Similarity Product: 528.0371647621988

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test